Anbio Biotechnology (NNNN) Cash & Equivalents (2023 - 2025)

Anbio Biotechnology's Cash & Equivalents history runs 3 years deep, the most recent figure standing at $7.8 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 33.96% year-over-year to $7.8 million; the TTM figure through Dec 2025 stood at $7.8 million (down 33.96% YoY), while the FY2025 annual figure was $7.8 million, down 33.96% from the prior year.
• Cash & Equivalents was $7.8 million for Q4 2025 at Anbio Biotechnology, down from $5348.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $5348.5 billion in Q2 2025 to a low of $7.8 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $1337.1 billion across 3 years, with a median of $10.7 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents advanced 21.4% in 2024, then tumbled 33.96% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $9.7 million in 2023, then advanced by 21.4% to $11.8 million in 2024, then sank by 33.96% to $7.8 million in 2025.
• The last three Cash & Equivalents figures came in at $7.8 million (Q4 2025), $5348.5 billion (Q2 2025), and $11.8 million (Q4 2024), per Business Quant data.